• Pulmatrix posted a net loss of $1.17 million, or $0.32 per share, for the three months ended March 31, narrowing from a $1.81 million loss, or $0.50 per share, a year earlier.
• Operating loss tightened to $1.29 million from $1.85 million, while general and administrative expense fell 27.49% to $1.29 million.
• Cash and cash equivalents totaled $3.32 million at March 31, down from $4.09 million at Dec. 31.
• Entered a merger agreement with Eos SENOLYTIX on March 26, with closing expected in the third quarter; raised $1 million in gross proceeds via a private placement of newly designated Series B Convertible Preferred Stock.
• Interim CEO Peter Ludlum said common stockholders are expected to hold about 6% of the combined company, without dilution from the preferred stock.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulmatrix Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605150820PR_NEWS_USPR_____NE60478) on May 15, 2026, and is solely responsible for the information contained therein.